Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

Operating Segments (Tables)

9 Months Ended

Sep. 30, 2023

Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2023 and 2022 (in thousands).

Segment Reporting for the Quarter Ended September 30, 2023

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	10,795		$	11,082		$	21,877		$	—		$	21,877
Intercompany revenues		4			88			92			—			—
Gross profit		1,494			3,055			4,549			—			4,549
Research and development		102			1			103			17			120
Interest income		—			—			—			146			146
Interest expense		(23	)		(1	)		(24	)		(65	)		(89	)
Interest expense-financing fees		—			—			—			(36	)		(36	)
Depreciation and amortization		584			88			672			14			686
Segment income (loss)		1,014			1,120			2,134			(1,888	)		246
Expenditures for segment assets		333			7			340			—			340	⁽³⁾

Segment Reporting for the Quarter Ended September 30, 2022

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	8,877		$	9,595		$	18,472		$	—		$	18,472
Intercompany revenues		28			16			44			—			—
Gross profit		1,967			1,103			3,070			—			3,070
Research and development		55			—			55			14			69
Interest income		—			—			—			29			29
Interest expense		(20	)		(2	)		(22	)		(25	)		(47	)
Interest expense-financing fees		—			—			—			(16	)		(16	)
Depreciation and amortization		387			87			474			23			497
Segment income (loss)		1,628			710			2,338			(1,514	)		824	⁽²⁾
Expenditures for segment assets		149			39			188			1			189	⁽⁴⁾

Segment Reporting for the Nine Months Ended September 30, 2023

										⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	33,223		$	33,793		$	67,016		$	—		$	67,016
Intercompany revenues		234			124			358			—			—
Gross profit		5,237			6,837			12,074			—			12,074
Research and development		260			11			271			69			340
Interest income		—			—			—			445			445
Interest expense		(68	)		(2	)		(70	)		(119	)		(189	)
Interest expense-financing fees		—			—			—			(80	)		(80	)
Depreciation and amortization		1,745			337			2,082			42			2,124
Segment income (loss)		2,619			2,933			5,552			(5,104	)		448
Expenditures for segment assets		1,376			10			1,386			—			1,386	⁽³⁾

Segment Reporting for the Nine Months Ended September 30, 2022

									⁽¹⁾
	Treatment			Services		Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	24,749		$	29,093	$	53,842		$	—		$	53,842
Intercompany revenues		28			43		71			—			—
Gross profit		4,168			3,422		7,590			—			7,590
Research and development		179			23		202			43			245
Interest income		—			—		—			69			69
Interest expense		(53	)		—		(53	)		(70	)		(123	)
Interest expense-financing fees		—			—		—			(44	)		(44	)
Depreciation and amortization		1,139			244		1,383			50			1,433
Segment income (loss)		1,766			1,580		3,346			(5,028	)		(1,682	)⁽²⁾
Expenditures for segment assets		819			127		946			1			947	⁽⁴⁾

⁽¹⁾	Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾	Includes approximately $1,975,000 recorded as other income under the Employee Retention Credit program under the CARES Act, as amended (see “Note 13 – Employee Retention Credit (“ERC”) below for a discussion of this refund amount).

⁽³⁾	Net of financed amount of $152,000 and $309,000 for the three and nine months ended September 30, 2023, respectively.

⁽⁴⁾	Net of financed amount of $0 and $114,000 for the three and nine months ended September 30, 2022, respectively.